Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 460
- Registration Number
- NCT00253955
- Locations
- 🇻🇪
Sanofi-Aventis, Caracas, Venezuela
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year
- Conditions
- Sleep Initiation and Maintenance DisordersInsomnia
- Interventions
- Drug: placebo
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-11-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1155
- Registration Number
- NCT00253903
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 476
- Registration Number
- NCT00252330
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
- Conditions
- Anxiety Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 360
- Registration Number
- NCT00252343
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 468
- Registration Number
- NCT00252356
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 460
- Registration Number
- NCT00250601
- Locations
- 🇺🇸
Administrative Office, Bridgewater, New Jersey, United States
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 365
- Registration Number
- NCT00250653
- Locations
- 🇺🇸
Administrative Office, Bridgewater, New Jersey, United States
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 465
- Registration Number
- NCT00250627
- Locations
- 🇵🇹
Sanofi-Aventis Administrative Office, Porto Salvo, Portugal
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 452
- Registration Number
- NCT00250614
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
- Conditions
- Atrial FibrillationVascular Risk
- Interventions
- Drug: placebo
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7554
- Registration Number
- NCT00249873
- Locations
- 🇧🇪
Sanofi-aventis Administrative Office, Diegem, Belgium
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇹Sanofi-Aventis, Wien, Austria